The Pharmaceutical Market: New Zealand

Date: January 31, 2013
Pages: 77
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P51525EFF4AEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: New Zealand
OVERVIEW OF THE PHARMACEUTICAL MARKET IN NEW ZEALAND

Low growth potential in New Zealand's pharmaceutical market will attract risk-averse investors. However, we note that regulatory delays in funding new medicines will hinder patients' access to pharmaceuticals, constituting a downside risk for drug companies looking to sell their products in the country.

Headline Expenditure Forecasts

Pharmaceuticals: NZD1.35bn (US$1.07bn) in 2011 to NZD1.36bn (US$1.04bn) in 2012; +1.2% in local currency and -2.7% in US dollar terms.

Healthcare: NZD19.34bn (US$15.29bn) in 2011 to NZD19.93bn (US$15.14bn) in 2012; +3.0% in local currency and -1.0% in US dollar terms.

Medical devices: NZD814mn (US$644mn) in 2011 to NZD832mn (US$632mn) in 20 12; +2.2% in local currency and -1.8% in US dollar terms.

Risk/Reward Rating: New Zealand was ranked 10th out of 18 pharmaceutical markets surveyed in the Asia region in Q1 13. Its score is dragged down by a low industry rewards score, due to its small and relatively low-growth potential market, and a low industry risks score because of its regulatory processes. In terms of Rewards, New Zealand is rated highly thanks to a stable economic and political environment and developed regulatory regimen.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

      New Zealand Pharmaceuticals & Healthcare Industry SWOT
      New Zealand Political SWOT
      New Zealand Economic SWOT
      New Zealand Business Environment SWOT

RISK/REWARD RATINGS

      Pharmaceuticals Risk/Reward Ratings
      Table: Asia Pacific – Regional Risk/Reward Ratings Q113
      Rewards
      Risks

NEW ZEALAND – MARKET SUMMARY

REGULATORY REGIME

      Intellectual Property Protection
      Pricing And Reimbursement
      Reimbursement Funding
      Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn)
      Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
      Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
      Recent Regulatory Developments

INDUSTRY DEVELOPMENTS

      Epidemiology
      Healthcare Sector
  Infrastructure
  Services
  Workforce
      Table: Regional Ranking of Projected Physicians, 2017
      Table: Projected Physicians, 2012-2017
  Latest Figures
      Active Medical Practitioners, 2005-2010

DISTRIBUTION CHANNELS

  Drug Wholesaling
      Leading Wholesalers
  Drug Retailing
  Leading Pharmacy Chains
      Table: Pharmacybrands Stores by Company & Region, 2010
  Radius Pharmacy
      Research and Development (R&D)
      Clinical Trials Sector
      Medical Devices
      Medical Devices Classes In New Zealand

INDUSTRY FORECAST SCENARIO

© BUSINESS MONITOR INTERNATIONAL LTDPAGE

      New Zealand Pharmaceuticals & Healthcare Report Q1 2013
    Pharmaceutical Market Forecast
    Table: Pharmaceutical Sales Indicators 2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure Indicators 2008-2016
    Table: Healthcare Governmental Indicators 2008-2016
    Table: Healthcare Private Indicators 2008-2016
    Key Growth Factors – Macroeconomic Forecast
    Table: Economic Activity
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators 2008-2016
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators 2008-2016
    Generic Drug Market Forecast
    Table: Generic Drug Sales Indicators 2008-2016
    OTC Drug Market Forecast
    Table: OTC Medicine Sales Indicators 2008-2016
  Pharmaceutical Trade Forecast
    Table: Exports and Imports Indicators 2008-2016
    Medical Device Market Forecast
    Table: Medical Devices Sales Indicators 2008-2016
    Other Healthcare Data
  Key Risks To BMI's Forecast Scenario

COMPETITIVE LANDSCAPE

    Pharmaceutical Industry
    Table: Licensed Medicine Manufacturers, 2008
    Company Developments

COMPANY PROFILES

    Douglas Pharmaceuticals
    New Zealand Pharmaceuticals

DEMOGRAPHIC OUTLOOK

    Population By Age Group
    Population By Age Group
    Key Population Ratios
    Rural and Urban Population

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Weighting
    Table: Weighting Of Components
Skip to top


Ask Your Question

The Pharmaceutical Market: New Zealand
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: